Feriotto G, Nastruzzi C, Barbieri R, Gambari R
Istituto di Chimica Biologica, Università di Ferrara, Italy.
Blut. 1988 Jul;57(1):25-30. doi: 10.1007/BF00320631.
Erythroid differentiation of human leukemic K 562 cells is inhibited by the iron chelator desferrioxamine (DF). In addition, desferrioxamine induces an increase of uptake of hemin. When hemin is added to the culture medium, the DF-mediated inhibitory effects on erythroid induction are reversed. Briefly, hemin allows hemoglobin synthesis by K 562 cells induced to erythroid differentiation by 1-beta-D-arabinofuranosylcytosine (ara-C) and treated with 12.5 micrograms/ml DF. In addition, it was found that hemin treatment leads to a reversion of inhibition of K 562 cell proliferation mediated by 50-75 micrograms/ml DF. This effect of hemin was also detected in other cultured human tumor cell lines (B-lymphoid, erythroleukemic and from breast carcinomas, melanomas and kidney carcinomas).
铁螯合剂去铁胺(DF)可抑制人白血病K 562细胞的红系分化。此外,去铁胺可诱导血红素摄取增加。当向培养基中添加血红素时,DF介导的对红系诱导的抑制作用会被逆转。简而言之,血红素可使由1-β-D-阿拉伯呋喃糖基胞嘧啶(ara-C)诱导并经12.5微克/毫升DF处理而发生红系分化的K 562细胞合成血红蛋白。此外,还发现血红素处理可逆转由50-75微克/毫升DF介导的对K 562细胞增殖的抑制作用。在其他培养的人肿瘤细胞系(B淋巴细胞系、红白血病细胞系以及来自乳腺癌、黑色素瘤和肾癌的细胞系)中也检测到了血红素的这种作用。